US Cholesterol Lowering Agents Market Report & Forecast: On the Edge of a Patent Cliff

US Cholesterol Lowering Agents Market Report & Forecast: On the Edge of a Patent Cliff

Report Format: PDF+Excel | Report ID: SR112025A275

With nine drugs expected to lose their patents between 2011 and 2016, the US Cholesterol Lowering Agents (Dyslipidemia) Market currently stands at the edge of a major patent cliff. IMARC Group, one of the world’s leading research and advisory firms, expects in its new report” US Cholesterol Lowering Agents Market Report & Forecast: On the Edge of a Patent Cliff” that despite a strong performance of Crestor (Rosuvatation), the avalanche of patent expiries and a thin drug pipeline will erode this market of sales worth more than US$ 8.7 billion in the next six years.

This report provides an analytical and statistical insight into the US Cholesterol Lowering agents Market. The study that has been undertaken using both desk-based as well as qualitative primary research has analyzed the following aspects of this market:

Key Aspects Analyzed:

Understanding the Epidemiology of Dyslipidemia in the US:

Focus of the Analysis:

  • Current and future size of the dyslipidemia patient pool
  • Current and  future prevalence of dyslipidemia
  • Current and future diagnosis rates for dyslipidemia
  • Current and future drug treatment rates for dyslipidemia


Comprehensive Evaluation of the US Cholesterol Lowering Agents Market:

Classes Covered: Statins, Fixed Dose Combinations, Ion Exchange Resins, Fibrates, Other Cholesterol Triglyceride Regulators, Omega-3 Acid Ethyl Esters and CETP Inhibitors

Molecules Covered: Atorvastatin, Rosuvastatin, Simvastatin, Pravastatin, Fluvastatin, Lovastatin, Pitavastatin, Ezetimibe/Simvastatin, ER Niacin/Simvastatin, Atorvastatin/Amlodipine, ER Naicin/Laropiprant, Ezetimibe/Atorvastatin, ER Niacin/Laropiprant/Simvastatin, Colesevelam, Cholestyramine, Colestipol, Fenofibrate, Fenofibric Acid, Gemfibrozil, Dalcetrapib, Anacetrapib

Focus of the Analysis for Each Class & Molecule:

  • Drug Overview
  • Historical Sales
  • Key Players and Brands in the Market
  • Patent Expiries and Generic Launch
  • Sales Forecast 


Comprehensive Evaluation of Generic Opportunities in the US Cholesterol Lowering Agents Market:

  • Historical Patent Expiries  and the Evolution of Generic Drugs
  • Historical Value and Volume share of Brands and Generics
  • Future Patent Expiries and Generic  Launches
  • Value and Volume Forecasts for Brands and Generics


Information Sources:

Information has been sourced from both primary and secondary sources:

  • Primary sources include industry surveys and face to face/telephone interviews with industry experts.
  • Secondary sources include proprietary databases and search engines. These sources include company websites and reports, books, trade journals, magazines, white papers, industry portals, government sources and access to more than 4000 paid databases.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
US Cholesterol Lowering Agents Market Report & Forecast: On the Edge of a Patent Cliff
Purchase Options
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials